FROM TUMOR BIOLOGY TO THERAPY DECISION IN THREE STEPS
The EndoPredict computer animation illustrates the functional principle of the EndoPredict test, which is used for determining the prognosis of breast cancer patients. The test consists of the molecular finger print determined by the gene expression within the tumor tissue and is combined with the clinical status of the tumor. In context with other patients’ data, the test result assists the treating physicians and the tumor board in their decision as to whether chemotherapy is necessary or not.
The computer animation answers the following questions:
- How do the various genes in the tumor influence the prognosis?
- How do the molecular fingerprint and the clinical data of tumor size and nodal status contribute to the EPclin score?
- What is the benefit a patient can expect from the chemotherapy?
1: 12-gene molecular score
- Description and influence of eight disease-relevant genes.
- Calculation of the 12-gene molecular score, the “molecular fingerprint”.
Possibility to simulate the influence of the individual genes by dragging the slider
2: EPclin score
- Calculation of the EPclin score by adding clinical data about tumor size and nodal status to the 12-gene molecular score.
- Statement on the risk of relapse within the next ten years.
- Assignment to the high-risk or low-risk group of relapse (indicating chemotherapy/no chemotherapy).
Dragging the slider gives an idea about the impact of the individual components on the overall test result.
The 12-gene molecular score slider can be varied by double-clicking the lock symbol for the 12-gene molecular score.
- Calculation of the “Chemobenefit” according to EBCTCG (Lancet 2012): Chemotherapy can reduce the risk of a metastasis by around one third.
- Visualization of the potential benefit of a chemo therapy and its life-threatening adverse effects.
Dragging the slider allows the user to obtain the statistically determined Chemobenefit for respective 12-gene molecular scores.